Merck & Co has returned all US marketing rights to ALK-Abello’s sublingual allergy tablets to the Danish company, casting a pall over the sector that has this year been dismayed by late-stage failures of new products and delays in drug development.
Developing the market for new allergy vaccines is proving difficult and has claimed another casualty, the US marketing partnership between Merck & Co. Inc. and Denmark’s ALK-Abello A/S, with the US Big Pharma returning all rights to ALK’s sublingual allergy immunotherapy tablets (SLIT) in North America.
The discontinuation followed a review of Merck’s strategic priorities and, after a six-month transition period, the rights to the SLIT...
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
